Salt and crystal form of pyrimidine compound, and preparation methods therefor

HK40083712BActive Publication Date: 2026-09-04SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62023072690
Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-07-28
Filing Date
2023-05-10
Publication Date
2026-09-04
Estimated Expiration
2041-07-22

AI Technical Summary

Technical Problem

Currently, there are no highly effective and low-toxicity RET inhibitors for the treatment of diseases related to RET activity, and crystalline forms lack properties such as bioavailability, physical and chemical stability for pharmaceutical use.

Method used

Develop salts and crystal forms of compound I, including multiple crystal forms of fumarate and p-toluenesulfonate, and prepare pharmaceutical compositions for treating related diseases by reacting with inorganic or organic acids to precipitate solids and separating and drying them.

Benefits of technology

The salt and crystal form of compound I exhibit good RET inhibitory activity, with improved bioavailability and stability, making it suitable for use as a pharmaceutical formulation and providing an effective means of treating RET-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

A salt and crystal form of a pyrimidine compound are provided, as well as a method for preparing the same. Specifically, a salt and crystal form of compound I are provided, including the crystal form of the salt, and a method for preparing them.
Need to check novelty before this filing date? Find Prior Art

Description

Invention Field

[0001] This invention relates to a salt and crystal form of a pyrimidine compound and a method for preparing the same. Specifically, this invention relates to a salt and crystal form of 2-(6-(6-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4-amine (compound I) and a method for preparing the same, wherein the salt may also be in various crystal forms. Background of the Invention

[0003] Protein kinases are a class of enzymes that catalyze the phosphorylation of proteins. Through mediating cell signaling processes, protein phosphorylation regulates cellular physiological activities, such as cell survival, proliferation, differentiation, apoptosis, and metabolism. Dysfunction of protein kinases is closely related to many diseases, including tumors, autoimmune diseases, inflammatory responses, central nervous system diseases, cardiovascular diseases, and diabetes.

[0004] RET is a proto-oncogene that encodes the RET protein, a transmembrane receptor-type tyrosine protein kinase. It consists of a cysteine-rich cadherin-like extracellular region (for ligand binding), a transmembrane region, and an intracellular structural region with tyrosine kinase activity. Activated RET protein can activate multiple downstream signaling pathways, including the RAS / RAF / ERK pathway, the PI3K / Akt pathway, and the JNK pathway, leading to cell proliferation, migration, and differentiation. Alterations in the RET gene (mutations or fusions) and aberrant expression of the wild-type RET gene result in abnormal activation of the RET protein, leading to overactivity of signaling pathways, which is one of the main mechanisms of carcinogenesis. Abnormally activated RET protein participates in the proliferation and invasion of different tumor cells through multiple signaling pathways, thus affecting tumor development and progression. Alterations in the RET gene have a more significant effect on downstream cascade reactions; RET gene mutations are mainly associated with medullary thyroid carcinoma and papillary thyroid carcinoma, while RET gene fusions are mainly associated with non-small cell lung cancer and chronic myeloid leukemia. Therefore, inhibiting RET activity has significant medical value (Nature Reviews Cancer, 2014, 14(3): 173-86).

[0005] RET inhibitors possess significant potential for treating and preventing various diseases, such as cancer and irritable bowel syndrome. Currently, five compounds are in clinical trials, and compounds from several other companies are in preclinical research. However, no RET-targeting inhibitors are currently on the market. Therefore, there is a need to develop new, highly effective, and low-toxicity RET inhibitors to meet clinical needs.

[0006] In addition, since crystalline forms may possess properties more suitable for medical and pharmaceutical applications under certain conditions, such as bioavailability, physical and / or chemical stability, purity and / or manufacturability, it is desirable in the art to develop various crystalline forms of RET inhibitors. Invention Overview

[0008] A first aspect of the invention provides a salt of compound I, comprising a fumarate of compound I and a p-toluenesulfonate of compound I.

[0009]

[0010] The salt of compound I in the first aspect of the present invention can be in various crystal forms, including the crystal form of compound I fumarate and the crystal form of compound I p-toluenesulfonate, such as crystal form A, crystal form B, crystal form C, crystal form D, crystal form F, crystal form G and crystal form A of compound I fumarate.

[0011] A second aspect of the invention provides compound I, which is in crystalline or amorphous form, preferably crystal form I, crystal form II, crystal form III, crystal form IV, crystal form V or crystal form VI.

[0012] A third aspect of the invention provides a method for preparing a salt of compound I, comprising reacting compound I in any solid form with an inorganic or organic acid to precipitate a solid, and subsequently separating and drying the precipitated solid.

[0013] A fourth aspect of the invention provides a pharmaceutical composition comprising a salt of the aforementioned compound I (e.g., compound I fumarate or p-toluenesulfonate, particularly compound I fumarate crystal form A, B, C, D, F, or G, or p-toluenesulfonate crystal form A) or compound I in crystalline form (e.g., crystal form I, II, III, IV, V, or VI), and one or more pharmaceutically acceptable carriers.

[0014] A fifth aspect of the invention provides a method for preventing or treating diseases or conditions associated with RET activity, comprising administering to an individual in need a therapeutically effective amount of a salt of the aforementioned compound I (e.g., compound I fumarate or p-toluenesulfonate, particularly compound I fumarate crystal form A, B, C, D, F, or G, or p-toluenesulfonate crystal form A) or compound I in its crystalline form (e.g., crystal form I, II, III, IV, V, or VI), or any combination thereof. The disease or condition associated with RET activity is irritable bowel syndrome, or cancer or tumor, including lung cancer (e.g., non-small cell lung cancer), breast cancer, head and neck cancer, rectal cancer, liver cancer, lymphoma, thyroid cancer (e.g., medullary thyroid carcinoma or papillary thyroid carcinoma), colon cancer, multiple myeloma, melanoma, glioma, brain tumor, or sarcoma.

[0015] A sixth aspect of the invention provides the use of a salt of the aforementioned compound I (e.g., compound I fumarate or p-toluenesulfonate, particularly compound I fumarate crystal form A, B, C, D, F, or G, or p-toluenesulfonate crystal form A) or compound I in its crystalline form (e.g., crystal form I, II, III, IV, V, or VI), or any combination thereof, or a pharmaceutical composition comprising the thereof, in the preparation of a medicament for the prevention or treatment of diseases or conditions associated with RET activity. The diseases or conditions associated with RET activity are irritable bowel syndrome, or cancer or tumors, including lung cancer (e.g., non-small cell lung cancer), breast cancer, head and neck cancer, rectal cancer, liver cancer, lymphoma, thyroid cancer (e.g., medullary thyroid carcinoma or papillary thyroid carcinoma), colon cancer, multiple myeloma, melanoma, glioma, brain tumor, or sarcoma.

[0016] The seventh aspect of the invention provides a salt of the aforementioned compound I (e.g., compound I fumarate or p-toluenesulfonate, particularly compound I fumarate crystal form A, B, C, D, F, or G, or p-toluenesulfonate crystal form A) or compound I in its crystalline form (e.g., crystal form I, II, III, IV, V, or VI), or any combination thereof, or a pharmaceutical composition comprising the thereof, for the prevention or treatment of diseases or conditions associated with RET activity. The diseases or conditions associated with RET activity are irritable bowel syndrome, or cancer or tumors, including lung cancer (e.g., non-small cell lung cancer), breast cancer, head and neck cancer, rectal cancer, liver cancer, lymphoma, thyroid cancer (e.g., medullary thyroid carcinoma or papillary thyroid carcinoma), colon cancer, multiple myeloma, melanoma, glioma, brain tumor, or sarcoma.

[0017] Compound I of the present invention exhibits good inhibitory activity against RET and possesses favorable pharmacokinetics, safety, and other properties. Furthermore, it has been found that crystalline forms of Compound I or its salts can be produced using certain solvents and / or methods. These crystalline forms, including substantially pure forms and mixtures of substantially pure forms, exhibit one or more advantageous characteristics. For example, they offer advantages in bioavailability and stability, making them suitable for use as active ingredients in pharmaceutical formulations. In particular, various crystalline forms of Compound I and its fumarate and p-toluenesulfonate offer one or more advantages such as improved manufacturing processes of Compound I, enhanced bioavailability and / or stability of Compound I, improved solubility of Compound I, improved hygroscopicity of the compound, and / or improved stability of pharmaceutical formulations containing Compound I, and extended shelf life.

[0018] Brief description of the attached figures

[0019] Figure 1 The X-ray powder diffraction (XRPD) pattern of the fumarate crystal form A of compound I prepared in method 1 of Example 2 is shown.

[0020] Figure 2 The XRPD pattern of compound I fumarate crystal form A prepared in Example 7 is shown.

[0021] Figure 3A The differential scanning calorimetry (DSC) spectrum of compound I fumarate crystal form A prepared in Example 7 is shown.

[0022] Figure 3B The thermogravimetric analysis (TGA) spectrum of compound I fumarate crystal form A prepared in Example 7 is shown.

[0023] Figure 4 The XRPD pattern of compound I fumarate crystal form B prepared in Example 3 is shown.

[0024] Figure 5 The DSC spectrum of compound I fumarate crystal form B prepared in Example 3 is shown.

[0025] Figure 6 The XRPD pattern of compound I fumarate crystal form C prepared in method 1 of Example 4 is shown.

[0026] Figure 7 The XRPD pattern of compound I p-toluenesulfonate crystal form A prepared in Example 5 is shown.

[0027] Figure 8 The DSC spectrum of compound I p-toluenesulfonate crystal form A prepared in Example 5 is shown.

[0028] Figure 9The TGA spectrum of compound I p-toluenesulfonate A prepared in Example 5 is shown.

[0029] Figure 10 The XRPD pattern of compound I, crystal form I, prepared in Example 6 is shown.

[0030] Figure 11 The DSC spectrum of crystal form I of compound I prepared in Example 6 is shown.

[0031] Figure 12 The TGA spectrum of compound I, crystal form I, prepared in Example 6 is shown.

[0032] Figure 13 The XRPD pattern of compound I fumarate crystal form D prepared in Example 8 is shown.

[0033] Figure 14 The DSC spectrum of compound I fumarate crystal form D prepared in Example 8 is shown.

[0034] Figure 15 The TGA spectrum of compound I fumarate crystal form D prepared in Example 8 is shown.

[0035] Figure 16 The XRPD pattern of compound I fumarate crystal form F prepared in Example 9 is shown.

[0036] Figure 17 The DSC spectrum of compound I fumarate crystal form F prepared in Example 9 is shown.

[0037] Figure 18 The TGA spectrum of compound I fumarate crystal form F prepared in Example 9 is shown.

[0038] Figure 19 The XRPD pattern of compound I fumarate crystal form G prepared in Example 10 is shown.

[0039] Figure 20 The DSC spectrum of compound I fumarate crystal form G prepared in Example 10 is shown.

[0040] Figure 21 The TGA spectrum of compound I fumarate crystal form G prepared in Example 10 is shown.

[0041] Figure 22 The XRPD pattern of compound I crystal form II prepared in Example 12 is shown.

[0042] Figure 23 The DSC spectrum of compound I, crystal form II, prepared in Example 12 is shown.

[0043] Figure 24The TGA spectrum of compound I crystal form II prepared in Example 12 is shown.

[0044] Figure 25 The XRPD pattern of compound I crystal form III prepared in Example 13 is shown.

[0045] Figure 26 The DSC spectrum of compound I, crystal form III, prepared in Example 13 is shown.

[0046] Figure 27 The TGA spectrum of compound I, crystal form III, prepared in Example 13 is shown.

[0047] Figure 28 The XRPD pattern of crystal form IV of compound I prepared in Example 14 is shown.

[0048] Figure 29 The DSC spectrum of crystal form IV of compound I prepared in Example 14 is shown.

[0049] Figure 30 The TGA spectrum of crystal form IV of compound I prepared in Example 14 is shown.

[0050] Figure 31 The XRPD pattern of crystal form V of compound I prepared in Example 15 is shown.

[0051] Figure 32 The DSC spectrum of crystal form V of compound I prepared in Example 15 is shown.

[0052] Figure 33 The TGA spectrum of crystal form V of compound I prepared in Example 15 is shown.

[0053] Figure 34 The XRPD pattern of crystal form VI of compound I prepared in Example 16 is shown.

[0054] Figure 35 The DSC spectrum of compound I crystal form VI prepared in Example 16 is shown.

[0055] Figure 36 The TGA spectrum of compound I crystal form VI prepared in Example 16 is shown.

[0056] Figure 37 The XRPD pattern of the amorphous compound I prepared in Example 11 is shown.

[0057] Figure 38 The XRPD pattern of compound I fumarate crystal form C prepared in Example 17 is shown.

[0058] Figure 39The DSC spectrum of compound I fumarate crystal form C prepared in Example 17 is shown.

[0059] Figure 40 The TGA spectrum of compound I fumarate crystal form C prepared in Example 17 is shown.

[0060] Figure 41 The DVS spectrum of compound I fumarate crystal form A prepared in Example 7 is shown.

[0061] Figure 42 The DVS spectrum of compound I crystal form VI prepared in Example 16 is shown. Invention Details

[0063] The present invention will be further explained below. It should be understood that the terms used are for descriptive purposes and not for limiting the invention.

[0064] definition

[0065] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of any conflict, the definitions herein shall prevail. When a quantity, concentration, or other value or parameter is expressed as a range, preferred range, or preferred upper and lower limits of a numerical value, it should be understood that this is equivalent to specifically disclosing any range by combining any pair of upper or preferred values ​​with any lower or preferred values ​​of a range. Unless otherwise stated, the numerical ranges listed herein are intended to include the endpoints of the range and all integers and fractions (decimals) within that range.

[0066] When used with a numerical variable, the term "about" usually means that the value of the variable and all values ​​of the variable are within the experimental error (e.g., within a 95% confidence interval for the mean) or within ±20%, ±10%, ±5%, or ±2% of the specified value.

[0067] The term "comprising," or similar expressions such as "including," "containing," and "having," is open-ended and does not exclude additional unlisted elements, steps, or components. The expression "consisting of," excludes any unspecified elements, steps, or components. The term "substantially consisting of," limits the scope to the specified elements, steps, or components, plus optional elements, steps, or components that do not materially affect the essential and novel features of the claimed subject matter. It should be understood that the term "comprising" and similar terms encompass the terms "substantially consisting of" and "consisting of."

[0068] As used herein, the terms “optional” or “optionally” mean that the event or situation subsequently described may or may not occur, including both the occurrence and non-occurrence of the event or situation.

[0069] Unless otherwise stated, all percentages, parts, etc. in this document are by weight.

[0070] As used herein, the term “crystal form” or “crystal” refers to any solid material exhibiting a three-dimensional arrangement, as opposed to amorphous solid materials, which produce characteristic XRPD patterns with clearly defined peaks.

[0071] As used herein, the term "seed crystal" refers to an additive that can form a crystal nucleus in a crystallization process, thereby accelerating or promoting the growth of enantiomers with the same crystal form or stereoconfiguration.

[0072] As used herein, the terms “X-ray powder diffraction pattern” or “XRPD pattern” refer to an experimentally observed diffraction pattern or the parameters, data, or values ​​derived from it. XRPD patterns are typically characterized by peak position (x-axis) and / or peak intensity (y-axis).

[0073] As used herein, the term “diffraction angle” or “2θ” refers to the peak position, expressed in degrees (°), based on the setup of an X-ray diffraction experiment, and is typically the horizontal axis unit in a diffraction pattern. If the incident beam is diffracted when it forms an angle θ with a lattice plane, the experimental setup requires recording the reflected beam at a 2θ angle. It should be understood that specific 2θ values ​​for a particular crystal form mentioned herein are intended to represent 2θ values ​​(expressed in degrees) measured using the X-ray diffraction experimental conditions described herein. For example, as described herein, using Cu-Kα (Kα1) 1.5406) ​​Monochromatic radiation. The XRPD spectra in this paper are preferably acquired using a PANalytacal X'Pert3 Powder X-ray powder diffractometer, and the transmission mode is preferably acquired using a PANalytacal X'Pert3 Powder X-ray powder diffractometer.

[0074] As used herein, the terms "substantially identical" or "substantially as shown in Figure ×" for X-ray diffraction peaks mean that representative peak positions and intensity variations are taken into account. For example, those skilled in the art will understand that peak positions (2θ) will show some variation, typically up to 0.1 to 0.2 degrees, and that the instrument used to measure diffraction will also cause some variation. Furthermore, those skilled in the art will understand that relative peak intensities will vary due to differences between instruments, as well as the degree of crystallinity, preferred orientation, the surface of the prepared sample, and other factors known to those skilled in the art.

[0075] Similarly, as used herein, the phrase “substantially as shown in Figure ×” for DSC and TGA spectra is intended to cover variations associated with these analytical techniques known to those skilled in the art. For example, for well-defined peaks in DSC spectra, there is typically a variation of up to ±0.2 °C, and even greater variations (e.g., up to ±1 °C) for broad peaks.

[0076] As used in this article, the term "room temperature" refers to 20℃±5℃.

[0077] As used in this article, the term “prevention” includes suppressing and delaying the onset of disease, and includes not only prevention before the development of disease, but also prevention of recurrence of disease after treatment.

[0078] As used herein, the term “treatment” means reversing, alleviating, or eliminating a targeted disease or symptom. A subject is considered successfully “treated” if, upon receiving a therapeutic amount of a salt of a compound of the present invention or a compound in its crystalline form, or a pharmaceutical composition of the present invention, at least one indicator and symptom of the subject shows observable and / or detectable relief and / or improvement. It is understood that treatment includes not only complete treatment but also the achievement of some biologically or medically relevant outcome without achieving complete treatment. Specifically, “treatment” means that a salt of a compound of the present invention or a compound in its crystalline form, or a pharmaceutical composition of the present invention, can achieve at least one of the following effects: (1) inhibiting disease (i.e., preventing further development of pathology and / or symptomology) in animals experiencing or exhibiting disease pathology or symptomology; (2) improving disease (i.e., reversing pathology and / or symptomology) in animals experiencing or exhibiting disease pathology or symptomology.

[0079] Salts and their crystalline forms

[0080] This invention provides a salt of compound I, wherein the salt is selected from fumarate and p-toluenesulfonate.

[0081]

[0082] In some embodiments, the salt of compound I is a fumarate of compound I, wherein the molar ratio of compound I to fumarate is 1:1.

[0083] Compound I fumarate crystal form A

[0084] In some embodiments, the salt of compound I is compound I fumarate crystal form A, whose XRPD pattern shows at maximum intensity at at least two, at least three, at least four, at least five, or at least six diffraction angles 2θ (°).

[0085] In some embodiments, the XRPD pattern of compound I fumarate crystal form A includes diffraction peaks at 2θ at approximately 5.44 ± 0.2°, 9.75 ± 0.2°, and / or 18.43 ± 0.2°. Preferably, the XRPD pattern of compound I fumarate crystal form A also includes diffraction peaks at 2θ at approximately 17.28 ± 0.2°, 18.13 ± 0.2°, 26.55 ± 0.2°, and / or 27.86 ± 0.2°. More preferably, the XRPD pattern of compound I fumarate crystal form A also includes diffraction peaks at 2θ at approximately 10.99 ± 0.2°, 12.09 ± 0.2°, 13.89 ± 0.2°, 14.87 ± 0.2°, 16.25 ± 0.2°, and / or 19.11 ± 0.2°. More preferably, the XRPD pattern of compound I fumarate crystal form A further includes diffraction peaks at 2θ at approximately 15.63±0.2°, 20.48±0.2°, 21.55±0.2°, 22.14±0.2°, 22.55±0.2°, 23.56±0.2°, 23.83±0.2° and / or 29.86±0.2°. Even more preferably, the XRPD pattern of compound I fumarate crystal form A further includes diffraction peaks at 2θ at approximately 12.84±0.2°, 16.56±0.2°, 16.74±0.2°, 17.02±0.2°, 19.70±0.2°, 21.08±0.2° and / or 25.64±0.2°.

[0086] In some embodiments, the XRPD pattern of compound I fumarate crystal form A is essentially as follows: Figure 1 As shown, and preferably as Figure 1 As shown.

[0087] In some embodiments, the XRPD pattern of compound I fumarate crystal form A is essentially as follows: Figure 2 As shown, and preferably as Figure 2 As shown.

[0088] In some embodiments, the onset temperature of the endothermic peak of compound I fumarate crystal form A is about 206.5℃ ± 5℃, preferably about 206.5℃ ± 2℃; preferably, the DSC spectrum of compound I fumarate crystal form A is substantially as follows: Figure 3A As shown, preferably as Figure 3A As shown.

[0089] In some embodiments, the TGA spectrum of compound I fumarate crystal form A is essentially as follows: Figure 3B As shown, preferably as Figure 3B As shown.

[0090] In some implementations, compound I fumarate crystal form A is an anhydrous form.

[0091] In some embodiments, the molar ratio of compound I to fumaric acid in fumarate crystal form A is 1:1.

[0092] In some embodiments, compound I fumarate crystal form A has two or all of the following properties:

[0093] (a) Basically as Figure 2 The XRPD map shown;

[0094] (b) Basically as Figure 3A The DSC spectrum shown; and

[0095] (c) Basically as Figure 3B The TGA spectrum shown.

[0096] Compound I fumarate crystal form B

[0097] In some embodiments, the salt of compound I is compound I fumarate crystal form B, whose XRPD pattern shows at most two, at least three, at least four, at least five, or at least six diffraction angles 2θ (°) at maximum intensity.

[0098] In some embodiments, the XRPD pattern of compound I fumarate crystal form B includes diffraction peaks at 2θ at approximately 9.12 ± 0.2°, 16.57 ± 0.2°, 24.78 ± 0.2°, and / or 25.74 ± 0.2°. Preferably, the XRPD pattern of compound I fumarate crystal form B also includes diffraction peaks at 2θ at approximately 15.64 ± 0.2°, 18.05 ± 0.2°, 21.13 ± 0.2°, and / or 22.08 ± 0.2°. More preferably, the XRPD pattern of compound I fumarate crystal form B also includes diffraction peaks at 2θ at approximately 13.62 ± 0.2°, 15.29 ± 0.2°, 21.81 ± 0.2°, 25.58 ± 0.2°, and / or 26.91 ± 0.2°. More preferably, the XRPD pattern of compound I fumarate crystal form B also includes diffraction peaks at 2θ at approximately 5.70±0.2°, 11.50±0.2°, 16.26±0.2°, 17.31±0.2°, 19.64±0.2°, 23.87±0.2° and / or 27.24±0.2°.

[0099] In some embodiments, the XRPD pattern of compound I fumarate crystal form B is essentially as follows: Figure 4 As shown, and preferably as Figure 4 As shown.

[0100] In some embodiments, the onset temperature of the endothermic peak of compound I fumarate crystal form B is approximately 202.21 °C ± 5 °C, and preferably approximately 202.21 °C ± 2 °C. More preferably, the DSC spectrum of compound I fumarate crystal form B is substantially as follows: Figure 5 As shown, preferably as Figure 5 As shown.

[0101] In some embodiments, compound I fumarate crystal form B has the following two properties:

[0102] (a) Basically as Figure 4 The XRPD map shown; and

[0103] (b) Basically as Figure 5 The DSC spectrum shown.

[0104] Compound I fumarate crystal form C

[0105] In some embodiments, the salt of compound I is compound I fumarate crystal form C, whose XRPD pattern shows at most two, at least three, at least four, at least five or at least six diffraction angles 2θ (°) at maximum intensity.

[0106] In some embodiments, the XRPD pattern of compound I fumarate crystal form C includes diffraction peaks at 2θ at approximately 9.13 ± 0.2° and / or 26.08 ± 0.2°. Preferably, the XRPD pattern of compound I fumarate crystal form C also includes diffraction peaks at 2θ at approximately 11.09 ± 0.2°, 17.63 ± 0.2°, 18.08 ± 0.2°, 20.21 ± 0.2°, 22.31 ± 0.2° and / or 27.92 ± 0.2°. More preferably, the XRPD pattern of compound I fumarate crystal form C also includes diffraction peaks at 2θ at approximately 10.05 ± 0.2°, 13.27 ± 0.2°, 13.78 ± 0.2°, 14.39 ± 0.2° and / or 17.24 ± 0.2°. More preferably, the XRPD pattern of compound I fumarate crystal form C also includes diffraction peaks at 2θ at approximately 8.58±0.2°, 16.84±0.2°, 23.12±0.2° and / or 25.13±0.2°.

[0107] In some embodiments, the XRPD pattern of compound I fumarate crystal form C is essentially as follows: Figure 6 As shown, and preferably as Figure 6 As shown.

[0108] In some embodiments, the XRPD pattern of compound I fumarate crystal form C is essentially as follows: Figure 38 As shown, and preferably as Figure 38 As shown.

[0109] In some embodiments, the DSC spectrum of compound I fumarate crystal form C is essentially as follows: Figure 39 As shown, preferably as Figure 39 As shown.

[0110] In some embodiments, the TGA spectrum of compound I fumarate crystal form C is essentially as follows: Figure 40 As shown, preferably as Figure 40 As shown.

[0111] Compound I fumarate crystal form D

[0112] In some embodiments, the XRPD pattern of compound I fumarate crystal form D is essentially as follows: Figure 13 As shown, and preferably as Figure 13 As shown.

[0113] In some embodiments, the DSC spectrum of compound I fumarate crystal form D is essentially as follows: Figure 14 As shown, preferably as Figure 14 As shown.

[0114] In some embodiments, the TGA spectrum of compound I fumarate crystal form D is essentially as follows: Figure 15 As shown, preferably as Figure 15 As shown.

[0115] Compound I fumarate crystal form F

[0116] In some embodiments, the XRPD pattern of compound I fumarate crystal form F is essentially as follows: Figure 16 As shown, and preferably as Figure 16 As shown.

[0117] In some embodiments, the DSC spectrum of compound I fumarate crystal form F is essentially as follows: Figure 17 As shown, preferably as Figure 17 As shown.

[0118] In some embodiments, the TGA spectrum of compound I fumarate crystal form F is essentially as follows: Figure 18 As shown, preferably as Figure 18 As shown.

[0119] Compound I fumarate crystal form G

[0120] In some embodiments, the XRPD pattern of compound I fumarate crystal form G is essentially as follows: Figure 19 As shown, and preferably as Figure 19 As shown.

[0121] In some embodiments, the DSC spectrum of compound I fumarate crystal form G is essentially as follows: Figure 20 As shown, preferably as Figure 20 As shown.

[0122] In some embodiments, the TGA spectrum of compound I fumarate crystal form G is essentially as follows: Figure 21 As shown, preferably as Figure 21 As shown.

[0123] Compound I p-Toluenesulfonate crystal form A

[0124] In some embodiments, the salt of compound I is compound I p-toluenesulfonate crystal form A, whose XRPD pattern shows at most two, at least three, at least four, at least five, or at least six diffraction angles 2θ (°) at maximum intensity.

[0125] In some embodiments, the XRPD pattern of compound I p-toluenesulfonate crystal form A includes diffraction peaks at 2θ at approximately 4.69 ± 0.2° and / or 13.87 ± 0.2°. Preferably, the XRPD pattern of compound I p-toluenesulfonate crystal form A also includes diffraction peaks at 2θ at approximately 16.98 ± 0.2°, 18.23 ± 0.2°, 19.27 ± 0.2°, 19.98 ± 0.2°, 22.08 ± 0.2°, 23.35 ± 0.2° and / or 25.78 ± 0.2°. More preferably, the XRPD pattern of compound I p-toluenesulfonate crystal form A also includes diffraction peaks at 2θ at approximately 8.25±0.2°, 12.23±0.2°, 15.60±0.2°, 17.83±0.2°, 22.49±0.2°, 24.30±0.2°, 25.17±0.2° and / or 28.13±0.2°. Even more preferably, the XRPD pattern of compound I p-toluenesulfonate crystal form A also includes diffraction peaks at 2θ at approximately 10.65±0.2°, 12.77±0.2° and / or 20.84±0.2°.

[0126] In some embodiments, the XRPD pattern of compound I p-toluenesulfonate crystal form A is essentially as follows: Figure 7 As shown, and preferably as Figure 7 As shown.

[0127] In some embodiments, the onset temperature of the endothermic peak of compound I p-toluenesulfonate crystal form A is approximately 43.71 °C ± 5 °C, and preferably approximately 43.71 °C ± 2 °C. More preferably, the DSC spectrum of compound I p-toluenesulfonate crystal form A is substantially as follows: Figure 8 As shown, preferably as Figure 8 As shown.

[0128] In some embodiments, the TGA spectrum of compound I p-toluenesulfonate crystal form A is essentially as follows: Figure 9 As shown, preferably as Figure 9 As shown.

[0129] In some embodiments, compound I p-toluenesulfonate crystal form A has two or all of the following properties:

[0130] (a) Basically as Figure 7 The XRPD map shown;

[0131] (b) Basically as Figure 8 The DSC spectrum shown; and

[0132] (c) Basically as Figure 9 The TGA spectrum shown.

[0133] Crystalline form of compound I

[0134] The present invention provides compound I, which is in crystalline form.

[0135] Compound I Crystal Form I

[0136] In some embodiments, compound I is compound I crystal form I, whose XRPD pattern shows at most two, at least three, at least four, at least five or at least six diffraction angles 2θ (°) at maximum intensity.

[0137] In some embodiments, the XRPD pattern of crystal form I of compound I includes diffraction peaks at 2θ at approximately 18.00 ± 0.2°, 19.55 ± 0.2°, 22.62 ± 0.2°, and / or 27.20 ± 0.2°. Preferably, the XRPD pattern of crystal form I of compound I also includes diffraction peaks at 2θ at approximately 5.53 ± 0.2°, 15.95 ± 0.2°, and / or 18.77 ± 0.2°. More preferably, the XRPD pattern of crystal form I of compound I also includes diffraction peaks at 2θ at approximately 14.12 ± 0.2°, 14.89 ± 0.2°, 16.89 ± 0.2°, 20.13 ± 0.2°, 20.36 ± 0.2°, 21.71 ± 0.2°, 24.86 ± 0.2°, and / or 25.67 ± 0.2°. More preferably, the XRPD pattern of crystal form I of compound I also includes diffraction peaks at 2θ at approximately 11.18±0.2°, 12.33±0.2°, 12.67±0.2°, 12.95±0.2°, 14.46±0.2°, 18.36±0.2°, 20.87±0.2°, 25.13±0.2°, 26.16±0.2°, 26.84±0.2°, 27.80±0.2° and / or 28.28±0.2°.

[0138] In some embodiments, the XRPD pattern of compound I crystal form I is essentially as follows: Figure 10 As shown, and preferably as Figure 10 As shown.

[0139] In some embodiments, the onset temperature of the endothermic peak of compound I, crystal form I, is approximately 190.79 °C ± 5 °C, and preferably approximately 190.79 °C ± 2 °C. More preferably, the DSC spectrum of compound I, crystal form I, is substantially as follows: Figure 11 As shown, preferably as Figure 11 As shown.

[0140] In some embodiments, the TGA spectrum of compound I, crystal form I, is essentially as follows: Figure 12 As shown, preferably as Figure 12 As shown.

[0141] In some implementations, compound I, crystal form I, is anhydrous.

[0142] In some embodiments, compound I, crystal form I, has two or all of the following properties:

[0143] (a) Basically as Figure 10 The XRPD map shown;

[0144] (b) Basically as Figure 11 The DSC spectrum shown; and

[0145] (c) Basically as Figure 12 The TGA spectrum shown.

[0146] Compound I Crystal Form II

[0147] In some embodiments, compound I is crystal form II of compound I, whose XRPD pattern shows at most two, at least three, or at least four diffraction angles 2θ (°) at maximum intensity.

[0148] In some embodiments, the XRPD pattern of compound I crystal form II includes diffraction peaks at 2θ at approximately 15.03±0.2°, 16.25±0.2°, 20.61±0.2°, 21.69±0.2° and / or 22.61±0.2°.

[0149] In some embodiments, the XRPD pattern of compound I crystal form II is essentially as follows: Figure 22 As shown, and preferably as Figure 22 As shown.

[0150] In some embodiments, the onset temperature of the endothermic peak of compound I crystal form II is approximately 128.4 °C ± 5 °C, preferably approximately 128.4 °C ± 2 °C. More preferably, the DSC spectrum of compound I crystal form II is substantially as follows: Figure 23 As shown, preferably as Figure 23 As shown.

[0151] In some embodiments, the TGA spectrum of compound I crystal form II is essentially as follows: Figure 24 As shown, preferably as Figure 24 As shown.

[0152] Compound I Crystal Form III

[0153] In some embodiments, the XRPD pattern of compound I crystal form III is essentially as follows: Figure 25 As shown, and preferably as Figure 25 As shown.

[0154] In some embodiments, the DSC spectrum of compound I crystal form III is essentially as follows: Figure 26 As shown, preferably as Figure 26 As shown.

[0155] In some embodiments, the TGA spectrum of compound I crystal form III is essentially as follows: Figure 27 As shown, preferably as Figure 27 As shown.

[0156] Compound I crystal form IV

[0157] In some embodiments, the XRPD pattern of compound I crystal form IV is essentially as follows: Figure 28 As shown, and preferably as Figure 28 As shown.

[0158] In some embodiments, the DSC spectrum of compound I crystal form IV is essentially as follows: Figure 29 As shown, preferably as Figure 29 As shown.

[0159] In some embodiments, the TGA spectrum of compound I crystal form IV is essentially as follows: Figure 30 As shown, preferably as Figure 30 As shown.

[0160] Compound I crystal form V

[0161] In some embodiments, the XRPD pattern of compound I crystal form V is essentially as follows: Figure 31 As shown, and preferably as Figure 31 As shown.

[0162] In some embodiments, the DSC spectrum of compound I crystal form V is essentially as follows: Figure 32 As shown, preferably as Figure 32 As shown.

[0163] In some embodiments, the TGA spectrum of compound I crystal form V is essentially as follows: Figure 33 As shown, preferably as Figure 33 As shown.

[0164] Compound I crystal form VI

[0165] In some embodiments, compound I is crystal form VI of compound I, whose XRPD pattern shows at most two, at least three, at least four, at least five or at least six diffraction angles 2θ (°) at maximum intensity.

[0166] In some embodiments, the XRPD pattern of crystal form VI of compound I includes diffraction peaks at 2θ at approximately 18.04 ± 0.2°, 19.56 ± 0.2°, 22.63 ± 0.2°, and / or 27.24 ± 0.2°. Preferably, the XRPD pattern of crystal form VI of compound I also includes diffraction peaks at 2θ at approximately 5.53 ± 0.2°, 15.91 ± 0.2°, and / or 18.70 ± 0.2°. More preferably, the XRPD pattern of crystal form VI of compound I also includes diffraction peaks at 2θ at approximately 14.14 ± 0.2°, 14.88 ± 0.2°, 16.90 ± 0.2°, and / or 20.37 ± 0.2°. More preferably, the XRPD pattern of crystal form VI of compound I also includes diffraction peaks at 2θ at approximately 11.17±0.2°, 12.95±0.2°, 20.89±0.2°, 25.15±0.2°, 26.21±0.2°, 26.93±0.2° and / or 27.81±0.2°.

[0167] In some embodiments, the XRPD pattern of compound I crystal form VI is essentially as follows: Figure 34 As shown, and preferably as Figure 34 As shown.

[0168] In some embodiments, the onset temperature of the endothermic peak of compound I crystal form VI is approximately 199.5℃ ± 5℃, preferably approximately 199.5℃ ± 2℃. More preferably, the DSC spectrum of compound I crystal form VI is substantially as follows: Figure 35 As shown, preferably as Figure 35 As shown.

[0169] In some embodiments, the TGA spectrum of compound I crystal form VI is essentially as follows: Figure 36 As shown, preferably as Figure 36 As shown.

[0170] In some implementations, compound I crystal form VI is anhydrous.

[0171] Crystal form preparation method

[0172] For Compound I and its salts of the present invention, the formation of various crystal forms depends to some extent on the selection of a specific solvent or combination of solvents, and the method of combining solvents may also affect the formation of crystal forms. Solvents that can be used to prepare the various crystal forms of the present invention include, but are not limited to, water, methanol, ethanol, isopropanol, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, ethyl acetate, N,N-dimethylformamide, and any mixture thereof.

[0173] The presence of impurities may influence the formation of one crystalline form of a compound, making it relatively more favorable for the formation of another crystalline form. Therefore, for the salts of Compound I of the present invention (e.g., fumarate), the presence of impurities in the system affects the specific crystal form formed during the salt-forming reaction of Compound I with an acid (e.g., fumaric acid).

[0174] The present invention provides a method for preparing one or more crystal forms of compound I or its salts as described above.

[0175] In some embodiments, a method is provided for preparing fumarate crystal form A of compound I, comprising reacting compound I with fumaric acid in a solvent, and then separating the resulting solid, wherein the solvent is methanol, tetrahydrofuran, or 2-methyltetrahydrofuran. Preferably, the reaction is carried out at an elevated temperature (e.g., about 40-70°C, preferably about 50-60°C, for example about 55°C).

[0176] In some embodiments, a method for preparing fumarate crystal form A of compound I is provided, which includes adding a solvent to compound I, followed by adding fumaric acid to react, and then separating the resulting solid, wherein the solvent is methanol, tetrahydrofuran or 2-methyltetrahydrofuran.

[0177] In some embodiments, a method for preparing fumarate form B of compound I is provided, comprising reacting compound I with fumaric acid in a solvent, and then separating the resulting solid, wherein the solvent is methanol. Preferably, the reaction is carried out at an elevated temperature (e.g., about 40-70°C, preferably about 50-60°C, for example about 55°C).

[0178] In some embodiments, a method for preparing fumarate crystal form B of compound I is provided, which includes adding a solvent to fumaric acid, then adding compound I to react, and then separating the resulting solid, wherein the solvent is methanol.

[0179] In some embodiments, a method for preparing fumarate crystal form C of compound I is provided, comprising mixing compound I fumarate (fumarate crystal form A or fumarate crystal form B) with a solvent, then stirring and separating the resulting solid, wherein the solvent is a mixture of ethanol and water. Preferably, stirring continues for a time sufficient for crystal form A or crystal form B to transform into crystal form C, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). Stirring can be carried out at room temperature.

[0180] In some embodiments, a method for preparing fumarate crystal form D of compound I is provided, comprising mixing fumarate of compound I (e.g., fumarate crystal form A) with a solvent, then stirring and separating the resulting solid, wherein the solvent is N,N-dimethylformamide. Preferably, the stirring continues for a time sufficient for crystal form A to transform into crystal form D, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). The stirring can be carried out at a temperature of 20-40°C (e.g., 20°C, 30°C, 40°C).

[0181] In some embodiments, a method for preparing fumarate crystal form F of compound I is provided, comprising mixing fumarate of compound I (e.g., fumarate crystal form A) with a solvent, then adding a poor solvent dropwise and separating the resulting solid, wherein the solvent is N,N-dimethylformamide and the poor solvent is water.

[0182] In some embodiments, a method for preparing fumarate form G of compound I is provided, comprising mixing fumarate of compound I (e.g., fumarate form F) with a solvent, then stirring and separating the resulting solid, wherein the solvent is n-heptane. Preferably, the stirring continues for a time sufficient for the transformation of form F to form G to occur, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). The stirring can be carried out at a temperature of 20-40°C (e.g., 20°C, 30°C, 40°C).

[0183] In some embodiments, a method for preparing p-toluenesulfonate crystal form A of compound I is provided, comprising reacting compound I with p-toluenesulfonic acid in a solvent, and then separating the resulting solid, wherein the solvent is acetonitrile. Preferably, the reaction is carried out at room temperature or at an elevated temperature, for example, about 20-45°C.

[0184] In some embodiments, a method for preparing crystal form I of compound I is provided, comprising mixing compound I with a solvent, then stirring and separating the resulting solid, wherein the solvent is ethyl acetate. Preferably, stirring is continued for a time sufficient to produce crystal form I, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). Stirring can be carried out at room temperature.

[0185] In some embodiments, a method for preparing crystal form II of compound I is provided, comprising mixing crystal form I (e.g., crystal form I) with a solvent, then stirring and separating the resulting solid, wherein the solvent is N,N-dimethylformamide. Preferably, stirring continues for a time sufficient for crystal form I to transform into crystal form II, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). Stirring can be carried out at a temperature of 20-40°C (e.g., 20°C, 30°C, 40°C).

[0186] In some embodiments, a method for preparing crystal form III of compound I is provided, comprising mixing compound I with a solvent, then stirring and separating the resulting solid, wherein the solvent is n-propanol. Preferably, stirring is continued for a time sufficient to produce crystal form III, for example 1-5 days, preferably 2-4 days, such as 3 days (72 h). Stirring can be carried out at room temperature.

[0187] In some embodiments, a method for preparing crystalline form IV of compound I is provided, comprising mixing compound I with a solvent, then stirring and separating the resulting solid, wherein the solvent is dichloromethane. Preferably, stirring is continued for a time sufficient to produce crystalline form IV, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). Stirring can be carried out at room temperature.

[0188] In some embodiments, a method for preparing crystal form V of compound I is provided, comprising mixing compound I with a solvent, then stirring and separating the resulting solid, wherein the solvent is acetonitrile. Preferably, stirring is continued for a time sufficient to produce crystal form V, for example, 1-5 days, preferably 2-4 days, such as 3 days (72 h). Stirring can be carried out at room temperature.

[0189] In some embodiments, a method for preparing crystal form VI of compound I is provided, comprising mixing compound I with a solvent, then allowing it to stand at room temperature and separating the resulting solid, wherein the solvent is methanol. Preferably, the time allowed to stand at room temperature is sufficient to produce crystal form VI, for example, 1 hour to 5 days, such as 5 hours, 10 hours, 1 day, 3 days, or 5 days.

[0190] The present invention will be further illustrated below through examples, which are intended only to illustrate the invention in order to better understand it, but are not intended to limit the scope of the invention.

[0191] Characterization of crystalline form

[0192] The crystalline or amorphous forms prepared in the examples were characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and nuclear magnetic resonance (NMR) spectroscopy.

[0193] Characterization methods:

[0194] (1)XRPD

[0195] XRPD patterns of each crystal form were acquired using a PANalytacal X'Pert3 Powder X-ray powder diffractometer in transmission mode. The 2θ range was 3.5° to 40° (CuKα emitter, wavelength...). The scanning current was 40mA and the scanning voltage was 40kV. Continuous transmission scanning was performed using absolute scan at room temperature with a step size of 0.013° and a dwell time of 50s.

[0196] (2) DSC

[0197] DSC spectra of each crystal form were acquired using a TA DSC2500 differential scanning calorimeter. The test temperature range was 35℃ to 250℃, with a heating rate of 10℃ / min. Nitrogen gas was used for purging during the test at a flow rate of 50 ml / min.

[0198] (3) TGA

[0199] TGA spectra of each crystal form were acquired using a METTLER TOLEDO TGA 1. The test temperature range was 35℃ to 500℃, with a heating rate of 10℃ / min. During the test, nitrogen was used for purging at a flow rate of 50 ml / min.

[0200] (4) Nuclear Magnetic Resonance (NMR) Spectroscopy

[0201] 1 H NMR was obtained using a Bruker superconducting nuclear magnetic resonance spectrometer (model AVACE III HD 400MHz). Example

[0202] Example 1: Preparation of 2-(6-(6-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (Compound I)

[0203]

[0204] Step 1: Preparation of 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (compound 1c)

[0205] Compounds 1a (1.50 g) and 1b (1.77 g) were added sequentially to a 100 mL single-necked flask, followed by DMSO (20.0 mL) and K₂CO₃ (5.83 g). The mixture was heated to 90 °C and stirred for 20 h under nitrogen protection. After the reaction was complete, the reaction solution was cooled to room temperature, diluted with 100 mL of water, and extracted with EA. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (PE:EA = 5:1) to give compound 1c (2.03 g). MS m / z (ESI): 354.1 [M+H] + .

[0206] Step 2: Preparation of 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (compound 1d)

[0207] Compound 1c (2.03 g), B2(pin)2 (4.01 g), KOAc (1.55 g), 1,4-dioxane (15.0 mL), and Pd(dppf)Cl2·DCM (644.67 mg) were added sequentially to a 100 mL single-necked flask and heated to 90 °C under nitrogen protection. After the reaction was complete, the reaction solution was cooled to room temperature, diluted with water (30 mL), and extracted with EA (40 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and purified by silica gel column chromatography (DCM:MeOH = 15:1) to give compound 1d (2.11 g). MS m / z (ESI): 402.3 [M+H] + .

[0208] Step 3: Preparation of 3-(5-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (compound 1f)

[0209] Compound 1e (950 mg) was dissolved in 1,4-dioxane (50.0 mL), followed by the addition of compound 1d (2.11 g), Cs₂CO₃ (3.15 g), and water (5.0 mL), and then Pd(dppf)Cl₂·DCM (477.83 mg). The mixture was heated to 90 °C for 14 h under nitrogen protection. After the reaction was complete, the reaction solution was cooled to room temperature, diluted with water (100 mL), and extracted with EA (60 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give compound 1f (587.0 mg). MS m / z (ESI): 463.3 [M+H] + .

[0210] Step 4: Preparation of 2-(6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (compound 1 g)

[0211] Compound 1f (1.36 g) was dissolved in DCM (20.0 mL), followed by the addition of TFA (20.0 mL). The reaction was carried out under nitrogen protection at room temperature. After the reaction was complete, the reaction solution was concentrated to dryness under reduced pressure and purified by Prep-HPLC to obtain 1 g of trifluoroacetate (587.0 mg). MS m / z (ESI): 363.3 [M+H] + .

[0212] Step 5: Preparation of 2-(6-(6-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (Compound I)

[0213] 1 g of trifluoroacetate (22.82 mg) and compound 2a (27.47 mg) were added to methanol (1.0 mL), followed by the sequential addition of triethylamine (4.45 mg) and sodium cyanoborohydride (13.86 mg), and the reaction was carried out at room temperature for 14 h. After the reaction was complete, the reaction solution was concentrated to dryness under reduced pressure and purified by Prep-HPLC to obtain compound I (7.0 mg) in an amorphous form. MS m / z (ESI): 538.3 [M+H] + .

[0214] 1H NMR (400MHz, DMSO-d6) δ11.98 (s, 1H), 9.66 (s, 1H), 9.12 (d, J=2.16Hz, 1H), 8.67 (dd, J=4.54, 0. 64Hz, 1H), 8.43 (dd, J=8.94, 2.28Hz, 1H), 8.41 (d, J=1.68Hz, 1H), 7.98 (dd, J=8.48, 2.12Hz, 1H) , 7.92 (d, J = 4.28Hz, 1H), 7.87 (d, J = 8.4Hz, 1H), 6.78 (d, J = 9.0Hz, 2H), 6.31 (br, 1H), 3.78-3.71 (m, 4H), 3.68-3.52 (m, 4H), 2.59-2.52 (m, 1H), 2.33 (s, 3H), 2.25 (s, 3H), 1.60 (d, J=8.36Hz, 1H).

[0215] Example 2: Preparation of Compound I fumarate crystal form A

[0216] Method 1: Compound I (10.0 g) prepared in Example 1 was added to a glass bottle, along with 200 mL of tetrahydrofuran, and the mixture was heated to 55°C. Fumaric acid (2.59 g) was added, and the mixture was kept at 55°C for further reaction. The mixture was then filtered to obtain compound I fumarate crystal form A.

[0217] The XRPD spectrum of the obtained compound I fumarate crystal form A is as follows: Figure 1 As shown, the XRPD peak positions and relative peak intensities are listed in Table 1.

[0218] Table 1: XRPD data of compound I fumarate crystal form A

[0219]

[0220] Method 2: Compound I (10.0 g) prepared in Example 1 was added to a glass bottle, along with 200 mL of methanol, and the temperature was raised to 55°C. Amorphous powder of Compound I as seed crystals was added, along with fumaric acid (2.59 g). The mixture was kept at 55°C and reacted, then filtered to obtain compound I fumarate crystal form A.

[0221] Method 3: Compound I (10.0 g) prepared in Example 1 was added to a glass bottle, along with 200 mL of 2-methyltetrahydrofuran, and the mixture was heated to 55°C. Fumaric acid (2.59 g) was added, and the mixture was kept at 55°C for further reaction. The mixture was then filtered to obtain compound I fumarate crystal form A.

[0222] The XRPD spectra of compound I fumarate crystal form A obtained by methods 2 and 3 are basically as follows: Figure 1 As shown.

[0223] Example 3: Preparation of Compound I fumarate crystal form B

[0224] Fumaric acid (3.24 g) was added to a glass bottle, followed by 200 mL of methanol, and the temperature was raised to 55 °C. Compound I (10.0 g) prepared in Example 1 was added in batches, and the reaction was maintained at 55 °C. The mixture was then filtered to obtain compound I fumarate crystal form B.

[0225] The XRPD pattern of compound I fumarate crystal form B is shown below. Figure 4 As shown, the XRPD peak positions and relative peak intensities are listed in Table 2.

[0226] The DSC spectrum of the obtained compound I fumarate crystal form B is as follows: Figure 5 As shown, the starting temperature of the sample's endothermic peak is approximately 202.21℃ ± 2℃.

[0227] Table 2: XRPD data of compound I fumarate crystal form B

[0228]

[0229] Example 4: Preparation of crystal form C of compound I fumarate

[0230] Method 1: Add 200 mg of compound I fumarate crystal form A to a glass bottle, add 4 mL of ethanol and 2 mL of water, stir at room temperature for 72 h, and then filter to obtain compound I fumarate crystal form C.

[0231] The XRPD pattern of the obtained compound I fumarate crystal form C is as follows: Figure 6 As shown, the XRPD peak positions and relative peak intensities are listed in Table 3.

[0232] Table 3: XRPD data of compound I fumarate crystal form C

[0233]

[0234]

[0235] Method 2: 200 mg of compound I fumarate crystal form B was added to a glass bottle, along with 4 mL of ethanol and 2 mL of water. The mixture was stirred at room temperature for 72 h, and then filtered to obtain compound I fumarate crystal form C. The XPRD pattern of the obtained compound I fumarate crystal form C is basically as follows: Figure 6 As shown.

[0236] Example 5: Preparation of compound I p-toluenesulfonate crystal form A

[0237] Compound I (50 mg) prepared in Example 1 was added to a glass bottle, along with 2 mL of acetonitrile and p-toluenesulfonic acid (37.2 mg), and stirred at 20-45 °C for 48 h. The mixture was then filtered to obtain p-toluenesulfonate crystal form A of compound I.

[0238] The XRPD pattern of compound I p-toluenesulfonate crystal form A is as follows: Figure 7 As shown, the XRPD peak positions and relative peak intensities are listed in Table 4.

[0239] The DSC spectrum of compound I p-toluenesulfonate crystal form A is as follows: Figure 8 As shown, the starting temperature of the sample's endothermic peak is approximately 43.71℃ ± 2℃.

[0240] The TGA spectrum of compound I p-toluenesulfonate crystal form A is as follows: Figure 9 As shown, this crystal form is an anhydrous substance.

[0241] Table 4: XRPD data of compound I p-toluenesulfonate crystal form A

[0242]

[0243] Example 6: Preparation of Crystal Form I of Compound I

[0244] Compound I (1.0 g) prepared in Example 1 was added to a glass bottle, 20 mL of ethyl acetate was added, and the mixture was stirred at room temperature for 72 h. The mixture was then filtered to obtain crystal form I of compound I.

[0245] The XRPD pattern of compound I, crystal form I is as follows: Figure 10 As shown, the XRPD peak positions and relative peak intensities are listed in Table 5.

[0246] The DSC spectrum of compound I, crystal form I is as follows: Figure 11 As shown, the starting temperature of the sample's endothermic peak is approximately 190.79℃±2℃.

[0247] The TGA spectrum of compound I, crystal form I is as follows: Figure 12 As shown, this crystal form is an anhydrous substance.

[0248] Table 5: XRPD data for crystal form I of compound I

[0249]

[0250] Example 7: Preparation of Compound I fumarate crystal form A

[0251] Compound I fumarate crystal form C (6 g) was stirred in anhydrous ethanol at 45 °C for more than 12 h to obtain compound I fumarate crystals. The crystals were characterized by nuclear magnetic resonance spectroscopy. 1 The H NMR data are as follows.

[0252] 1 H NMR (400MHz, DMSO-d6) δ12.68 (br, 3H), 9.65 (s, 1H), 9.13 (d, J = 2.0Hz, 1H), 8.66 (d, J = 4.4Hz, 1H), 8.44 (dd, J=8.8, 2.0Hz, 1H), 8.41 (d, J=1.2Hz, 1H), 7.97 (dd, J=8.4, 1.6Hz, 1H), 7.91 (d, J=4.4Hz, 1 H), 7.86 (d, J=8.4Hz, 1H), 6.81 (br, 1H), 6.77 (d, J=8.8Hz, 1H), 6.62 (s, 2H), 6.30 (br, 1H), 3.79-3 .76 (m, 4H), 3.67-3.60 (m, 4H), 2.62-2.56 (m, 1H), 2.33 (s, 3H), 2.25 (s, 3H), 1.61 (d, J=8.4Hz, 1H).

[0253] The XRPD spectrum of the obtained crystal is as follows: Figure 2 As shown, the XRPD peak positions and relative peak intensities are listed in Table 6. The obtained XRPD data indicate that the crystal is fumarate form A of compound I.

[0254] DSC spectrum as follows Figure 3A As shown, the starting temperature of the sample's endothermic peak is approximately 206.5℃ ± 2℃.

[0255] TGA spectrum as shown Figure 3B As shown, this crystal form is an anhydrous substance.

[0256] Table 6: XRPD data of compound I fumarate crystal form A

[0257]

[0258] Example 8: Preparation of crystal form D of compound I fumarate

[0259] Approximately 200 mg of compound I fumarate crystal form A was suspended and stirred in DMF (approximately 1 ml) at 20°C or 40°C for 72 h to obtain compound I fumarate crystal form D. The XRPD spectrum of the obtained crystal form D is shown below. Figure 13 As shown, the XRPD peak positions and relative peak intensities are listed in Table 7. The DSC spectrum is shown below. Figure 14 As shown, the onset temperature of the sample's endothermic peak is approximately 159.0℃ ± 2℃. The TGA spectrum is shown below. Figure 15 As shown, when heated to 180°C, the weight loss is approximately 11%.

[0260] Table 7: XRPD data of compound I fumarate crystal form D

[0261]

[0262]

[0263] Example 9: Preparation of compound I fumarate crystal form F

[0264] 4.0 g of compound I fumarate crystal form A was dissolved in 60 ml of hot DMF, and 140 ml of purified water was added. After adding seed crystals of compound I fumarate crystal form F (by adding 1.5 ml of water to 500 μl of a solution containing approximately 100 mg / ml of compound I fumarate to precipitate seed crystals of form F), 40 ml of purified water was added dropwise. The solid was filtered and dried to obtain 2.67 g of compound I fumarate crystal form F. The XRPD spectrum of the obtained crystal form F is shown below. Figure 16 As shown, the XRPD peak positions and relative peak intensities are listed in Table 8. The DSC spectrum is shown below. Figure 17 As shown, a broad endothermic peak exists between 40 and 150 °C. The TGA spectrum is as follows. Figure 18 As shown, heating to 100°C results in a weight loss of approximately 10%.

[0265] Table 8: XRPD data of fumarate form F of compound I

[0266]

[0267] Example 10: Preparation of Compound I fumarate crystal form G

[0268] Approximately 100 mg of compound I fumarate crystal form F was suspended and stirred in 1 ml of n-heptane at 40 °C for 72 h. The solid was filtered and dried to obtain compound I fumarate crystal form G. The XRPD spectrum of the obtained crystal form G is shown below. Figure 19 As shown, the XRPD peak positions and relative peak intensities are listed in Table 9. The DSC spectrum is shown below. Figure 20 As shown, a broad endothermic peak exists between 40 and 140 °C. The TGA spectrum is as follows. Figure 21 As shown, heating to 100°C results in a weight loss of approximately 10%.

[0269] Table 9: XRPD data of compound I fumarate crystal form G

[0270]

[0271] Example 11: Preparation of the amorphous form of compound I

[0272] Compound I, crystal form I (3.3 g), was dissolved in tetrahydrofuran (100 ml). The solvent was rapidly removed by rotary evaporation at 50 °C to obtain the amorphous form of compound I. The XRPD spectrum of the obtained amorphous form is shown below. Figure 37 As shown.

[0273] Example 12: Preparation of Crystal Form II of Compound I

[0274] Approximately 100 mg of compound I (crystal form I) was suspended in 1 ml of DMF and stirred at 40 °C for 72 h. After centrifugation, the solid was washed with n-heptane and dried to obtain compound I (crystal form II). The XRPD spectrum of the obtained crystal form II is shown below. Figure 22 As shown, the XRPD peak positions and relative peak intensities are listed in Table 10. The DSC spectrum is shown below. Figure 23 As shown. TGA spectrum as follows. Figure 24 As shown, when heated to 160°C, the weight loss is 13.6%.

[0275] Table 10: XRPD data for compound I crystal form II

[0276]

[0277]

[0278] Example 13: Preparation of Compound I Crystal Form III

[0279] Compound I, in its amorphous form (approximately 100 mg), was suspended in 1 ml of n-propanol and stirred at 20 °C for 72 h. After centrifugation and drying, crystalline form III of compound I was obtained. The XRPD spectrum of crystalline form III is shown below. Figure 25 As shown, the XRPD peak positions and relative peak intensities are listed in Table 11. The DSC spectrum is shown below. Figure 26 As shown. TGA spectrum as follows. Figure 27 As shown, when heated to 160°C, the weight loss is 10.4%.

[0280] Table 11: XRPD data for compound I crystal form III

[0281]

[0282]

[0283] Example 14: Preparation of Crystal Form IV of Compound I

[0284] The amorphous form of compound I (approximately 100 mg) was suspended in 1 ml of dichloromethane and stirred at 20 °C for 72 h. After centrifugation and drying, crystalline form IV of compound I was obtained. The XRPD spectrum of crystalline form IV is shown below. Figure 28 As shown, the XRPD peak positions and relative peak intensities are listed in Table 12. The DSC spectrum is shown below. Figure 29 As shown. TGA spectrum as follows. Figure 30 As shown, when heated to 220°C, the weight loss is approximately 4%.

[0285] Table 12: XRPD data for crystal form IV of compound I

[0286]

[0287] Example 15: Preparation of crystal form V of compound I

[0288] The amorphous form of compound I (approximately 100 mg) was suspended in 1 ml of acetonitrile and stirred at 20 °C for 72 h. After centrifugation and drying, crystalline form V of compound I was obtained. The XRPD spectrum of crystalline form V is shown below. Figure 31 As shown, the XRPD peak positions and relative peak intensities are listed in Table 13. The DSC spectrum is shown below. Figure 32 As shown. TGA spectrum as follows. Figure 33 As shown, when heated to 80°C, the weight loss is approximately 5%.

[0289] Table 13: XRPD data for crystal form V of compound I

[0290]

[0291]

[0292] Example 16: Preparation of Crystal Form VI of Compound I

[0293] The amorphous form of compound I (approximately 100 mg) was dissolved in 1 mg of anhydrous methanol and slowly evaporated to obtain crystalline form VI of compound I. The XRPD spectrum of the obtained crystalline form VI is shown below. Figure 34 As shown, the XRPD peak positions and relative peak intensities are listed in Table 14. The DSC spectrum is shown below. Figure 35 As shown, the onset temperature of the sample's endothermic peak is approximately 199.5℃. The TGA spectrum is shown below. Figure 36 As shown, the sample showed almost no weight loss before melting, indicating that crystal form VI is an amorphous form.

[0294] Table 14: XRPD data for crystal form VI of compound I

[0295]

[0296] Example 17: Preparation of crystal form C of compound I fumarate

[0297] 6 g of compound I fumarate crystal form A was added to a glass bottle, along with 30 mL of ethanol and 30 mL of water. The mixture was stirred at 45 °C for 12 h, and then filtered to obtain compound I fumarate crystal form C. The XRPD spectrum of the obtained crystal form C is shown below. Figure 38 As shown, the XRPD peak positions and relative peak intensities are listed in Table 15. The DSC spectrum is shown below. Figure 39 As shown. TGA spectrum as follows. Figure 40 As shown, when heated to 100°C, the weight loss is approximately 7%.

[0298] Table 15: XRPD data of compound I fumarate crystal form C

[0299]

[0300]

[0301] Experimental Example 1: Determination of the solubility of compound I fumarate crystal form A

[0302] The solubility data of compound I fumarate crystal form A at different pH values ​​are listed in Table 16.

[0303] Table 16: Solubility of Compound I Fumarate Crystal Form A at Different pH

[0304]

[0305] Experimental Example 2: Stability Test of Compound I Fumarate Crystal Form A

[0306] The stability data of compound I fumarate crystal form A under influencing conditions are listed in Table 17 (HPLC purity is area-normalized purity).

[0307] Table 17: Stability Test of Fumarate Form A of Compound I

[0308]

[0309] The experimental results show that compound I, crystal form A, has good stability under both high temperature and high humidity conditions.

[0310] Experimental Example 3: Dynamic water adsorption test of fumarate form A of compound I

[0311] Equipment Information: SMS (Surface Measurement Systems) Intrinsic

[0312] Test method: Temperature 25℃; Protective gas N2; Maximum equilibration time 120 min; RH range 0%-90%-0%.

[0313] The DVS spectrum of compound I fumarate crystal form A is as follows: Figure 41 As shown, when the humidity increases to 90%, compound I fumarate crystal form A adsorbs approximately 0.7% water. When the humidity decreases from 90% to 0%, the adsorbed water is completely desorbed. The crystal form did not change before and after the DVS test.

[0314] Experimental Example 4: Dynamic water adsorption test of crystal form VI of compound I

[0315] Equipment Information: SMS (Surface Measurement Systems) Intrinsic

[0316] Test method: Temperature 25℃; Protective gas N2; Maximum equilibration time 120 min; RH range 0%-90%-0%.

[0317] The DVS spectrum of compound I crystal form VI is as follows Figure 42 As shown, when the humidity increases to 90%, compound I crystal form VI adsorbs approximately 0.6% water. When the humidity decreases from 90% to 0%, the adsorbed water is completely desorbed. The crystal form did not change before and after the DVS test.

[0318] Experimental Example 5: Inhibitory effect of compound I fumarate crystal form A on RET enzyme

[0319] The effects of compound I fumarate crystal form A on RET wild-type and RET mutant (RET) were determined using the HTRF KinEASE-TK (Cisbio) kit. V804M RET V804L and RET M918T The activity inhibition of RET fusion types (CCDC6-RET and KIF5B-RET) and RET fusion types.

[0320] The different types of RET enzymes were pre-incubated with different concentrations of test compounds (9 concentration points) at room temperature for 30 min, followed by the addition of substrate and adenosine triphosphate (ATP) to initiate the reaction. After incubation at room temperature for 40 min, TK antibody-caecin compound and antibiotic streptavidin-XL665 were added, and the reaction was performed after incubation at room temperature for 60 min. The reaction conditions for different types of RET enzymes are shown in the table below:

[0321] RET enzyme type RET(nM) ATP (μM) TK-substrate (μM) RET 0.2 30 1 <![CDATA[RET V804M ]]> 0.6 15 1 <![CDATA[RET V804L ]]> 0.6 10 1 <![CDATA[RET M918T ]]> 0.3 15 1 CCDC6-RET 0.3 15 1 KIF5B-RET 0.6 25 1

[0322] Using the solvent group (DMSO) as a negative control and the buffer group (without RET enzyme) as a blank control, the relative percentage of inhibitory activity of different concentrations of the compound was calculated according to the following formula:

[0323] Relative inhibition percentage = 1 - (different concentrations of compound group - blank control) / (negative control - blank control) * 100%

[0324] The relative inhibitory activity percentage of different compound concentrations was plotted against the compound concentration. The curve was fitted using a four-parameter model, and the IC was calculated using the following formula. 50 value:

[0325] y = min + (max - min) / (1 + (x / IC) 50 )^(-Hillslope))

[0326] Where y is the relative inhibitory activity percentage, max and min are the maximum and minimum values ​​of the fitted curve, respectively, x is the logarithmic concentration of the compound, and Hillslope is the slope of the curve.

[0327] Compound I, fumarate form A of this application, is effective against wild-type RET enzyme and RET... V804M Enzymes, RET V804L Enzymes, RET M918T The inhibitory effects of enzymes, CCDC6-RET enzyme, and KIF5B-RET enzyme are shown in the table below.

[0328] The inhibitory IC50 of compound I fumarate crystal form A on various types of RET enzymes 50 value

[0329] RET enzyme type <![CDATA[Inhibitory IC of RET enzyme 50 (nM)]]> RET 0.56±0.09 <![CDATA[RET V804M ]]> 0.60±0.20 <![CDATA[RET V804L ]]> 1.59±0.51 <![CDATA[RET M918T ]]> 2.23±0.64 CCDC6-RET 2.48±1.00 KIF5B-RET 0.56±0.10

[0330] The data in the table above indicate that compound I fumarate crystal form A is effective against the six types of RET kinases tested (RET, RET2, RET3, RET4, RET5, RET6, RET7, RET8, RET9, RET10 ... V804M RET V804L RET M918T It has a significant inhibitory effect on the enzyme activity of CCDC6-RET and KIF5B-RET.

[0331] Experimental Example 6: Pharmacokinetic Study of Compound I Fumarate Crystal Form A in Mice

[0332] Six female Balb / c mice were administered compound I (fumarate form A) orally by gavage at a dose of 1 mg / kg. The compound was first dissolved in 0.5% methylcellulose solution and sonicated to ensure complete dissolution or homogeneous suspension. 0.2 ml of whole blood (anticoagulated with EDTA-K2) was collected intravenously at 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 16 h, and 24 h post-administration. The collected whole blood was temporarily stored on ice and centrifuged for 10 min within 2 h to separate the plasma (4°C). The collected plasma was stored at -80°C for analysis.

[0333] The plasma concentration of compound I was determined by LC-MS / MS, with a linear range of 10–10000 ng / ml. The calculated pharmacokinetic parameters are shown in the table below.

[0334] Pharmacokinetic study of compound I fumarate crystal form A in mice

[0335] parameter unit PO (1 mg / kg) <![CDATA[AUC INF ]]> h*ng / ml 11381 AUClast h*ng / ml 11354 <![CDATA[C max ]]> ng / ml 2060 Vd ml / kg 356 Cl ml / h / kg 88 <![CDATA[t 1 / 2 ]]> h 2.81 <![CDATA[T max ]]> h 1.00

[0336] The data in the table above indicate that compound I fumarate crystal form A has excellent pharmacokinetic properties in mice.

[0337] The above detailed embodiments provide a further detailed description of the present invention. However, it should not be construed as limiting the scope of the present invention to the listed embodiments; all technical solutions implemented based on the content of the present invention fall within the scope of the present invention.

Claims

1. A salt of compound I, which is the fumarate crystal form A of compound I. , Its features The XRPD pattern of crystal form A includes diffraction peaks at 2θ at 5.44±0.2°, 9.75±0.2°, 18.43±0.2°, 17.28±0.2°, 18.13±0.2°, 26.55±0.2°, 27.86±0.2°, 10.99±0.2°, 12.09±0.2°, 13.89±0.2°, 14.87±0.2°, 16.25±0.2°, and 19.11±0.2°.

2. The salt of compound I as claimed in claim 1, wherein the fumarate crystal form A of compound I further comprises diffraction peaks at 2θ at 15.63±0.2°, 20.48±0.2°, 21.55±0.2°, 22.14±0.2°, 22.55±0.2°, 23.56±0.2°, 23.83±0.2° and 29.86±0.2°.

3. The salt of compound I as claimed in claim 1, wherein the fumarate crystal form A of compound I further includes diffraction peaks at 2θ at 12.84±0.2°, 16.56±0.2°, 16.74±0.2°, 17.02±0.2°, 19.70±0.2°, 21.08±0.2° and 25.64±0.2°.

4. The salt of compound I as described in claim 1, characterized in that... The XRPD pattern of crystal form A is basically as shown in Figure 1.

5. The salt of compound I as described in claim 1, characterized in that... The XRPD pattern of crystal form A is shown in Figure 1.

6. A salt of compound I, which is the fumarate form B of compound I. , Its features The XRPD pattern of crystal form B includes diffraction peaks at 2θ at 9.12±0.2°, 16.57±0.2°, 24.78±0.2°, 25.74±0.2°, 15.64±0.2°, 18.05±0.2°, 21.13±0.2°, 22.08±0.2°, 13.62±0.2°, 15.29±0.2°, 21.81±0.2°, 25.58±0.2°, and 26.91±0.2°.

7. The salt of compound I as claimed in claim 6, wherein the XRPD pattern of said crystal form B further includes diffraction peaks at 2θ at 5.70±0.2°, 11.50±0.2°, 16.26±0.2°, 17.31±0.2°, 19.64±0.2°, 23.87±0.2° and 27.24±0.2°.

8. The salt of compound I as claimed in claim 6, wherein the XRPD pattern of crystal form B is substantially as shown in Figure 4.

9. The salt of compound I as claimed in claim 6, wherein the XRPD pattern of crystal form B is shown in Figure 4.

10. A salt of compound I, which is the fumarate crystal form C of compound I. , Its features The XRPD pattern of crystal form C includes diffraction peaks at 2θ at 9.13±0.2°, 26.08±0.2°, 11.09±0.2°, 17.63±0.2°, 18.08±0.2°, 20.21±0.2°, 22.31±0.2°, 27.92±0.2°, 10.05±0.2°, 13.27±0.2°, 13.78±0.2°, 14.39±0.2°, and 17.24±0.2°.

11. The salt of compound I as claimed in claim 10, wherein the XRPD pattern of said crystal form C further includes diffraction peaks at 2θ at 8.58±0.2°, 16.84±0.2°, 23.12±0.2° and 25.13±0.2°.

12. The salt of compound I as claimed in claim 10, wherein the XRPD pattern of crystal form C is substantially as shown in Figure 6.

13. The salt of compound I as claimed in claim 10, wherein the XRPD pattern of crystal form C is shown in Figure 6.

14. A salt of compound I, which is compound I p-toluenesulfonate crystal form A. , Its features The XRPD pattern of crystal form A includes diffraction peaks at 2θ at 4.69±0.2°, 13.87±0.2°, 16.98±0.2°, 18.23±0.2°, 19.27±0.2°, 19.98±0.2°, 22.08±0.2°, 23.35±0.2°, 25.78±0.2°, 8.25±0.2°, 12.23±0.2°, 15.60±0.2°, 17.83±0.2°, 22.49±0.2°, 24.30±0.2°, 25.17±0.2°, and 28.13±0.2°.

15. The salt of compound I as claimed in claim 14, wherein the XRPD pattern of the p-toluenesulfonate crystal form A further includes diffraction peaks at 2θ at 10.65±0.2°, 12.77±0.2° and 20.84±0.2°.

16. The salt of compound I as described in claim 14, characterized in that... The XRPD pattern of crystal form A is basically as shown in Figure 7.

17. The salt of compound I as claimed in claim 14, characterized in that... The XRPD pattern of crystal form A is shown in Figure 7.

18. Compound I, which is in crystalline form I. , The XRPD pattern of crystal form I includes diffraction peaks at 2θ at 18.00±0.2°, 19.55±0.2°, 22.62±0.2°, 27.20±0.2°, 5.53±0.2°, 15.95±0.2°, 18.77±0.2°, 14.12±0.2°, 14.89±0.2°, 16.89±0.2°, 20.13±0.2°, 20.36±0.2°, 21.71±0.2°, 24.86±0.2°, and 25.67±0.2°.

19. Compound I as claimed in claim 18, characterized in that... The XRPD pattern of crystal form I also includes diffraction peaks at 2θ at 11.18±0.2°, 12.33±0.2°, 12.67±0.2°, 12.95±0.2°, 14.46±0.2°, 18.36±0.2°, 20.87±0.2°, 25.13±0.2°, 26.16±0.2°, 26.84±0.2°, 27.80±0.2°, and 28.28±0.2°.

20. Compound I as claimed in claim 18, characterized in that... The XRPD pattern of crystal form I is basically as shown in Figure 10.

21. Compound I as claimed in claim 18, characterized in that... The XRPD pattern of crystal form I is shown in Figure 10.

22. A pharmaceutical composition comprising a salt of compound I according to any one of claims 1-17 or compound I according to any one of claims 18-21, and one or more pharmaceutically acceptable carriers.

23. Use of a salt of compound I of any one of claims 1-17, or compound I of any one of claims 18-21, or the pharmaceutical composition of claim 22, or any combination thereof, for the preparation of a medicament for the prevention or treatment of a disease or condition associated with RET activity, wherein the disease or condition associated with RET activity is irritable bowel syndrome, or cancer or tumor.

24. The use as described in claim 23, wherein the cancer or tumor is selected from lung cancer, breast cancer, head and neck cancer, rectal cancer, liver cancer, lymphoma, thyroid cancer, colon cancer, multiple myeloma, melanoma, glioma, brain tumor or sarcoma.

25. The use as described in claim 24, wherein, The lung cancer is non-small cell lung cancer; the thyroid cancer is medullary thyroid carcinoma or papillary thyroid carcinoma.